Crystalline solid and amorphous forms of (−)-halofenate and methods related thereto
    3.
    发明授权
    Crystalline solid and amorphous forms of (−)-halofenate and methods related thereto 有权
    ( - ) - 卤化物的结晶固体和无定形形式及其相关方法

    公开(公告)号:US08507719B2

    公开(公告)日:2013-08-13

    申请号:US13470142

    申请日:2012-05-11

    IPC分类号: C07C67/02

    摘要: The present invention provides crystalline solid and amorphous forms of (−)-halofenate. The crystalline solid forms may be used in various pharmaceutical compositions, and are particularly effective for the prevention and/or treatment of conditions associated with blood lipid deposition in a mammal, particularly those diseases related to Type 2 diabetes and hyperlipidemia. The invention also relates to a method for preventing or treating Type 2 diabetes and hyperlipidemia in a mammal comprising the step of administering a therapeutically effective amount of crystalline solid and amorphous forms of (−)-halofenate.

    摘要翻译: 本发明提供( - ) - 卤代苯甲酸酯的结晶固体和无定形形式。 结晶固体形式可以用于各种药物组合物中,并且对于预防和/或治疗与哺乳动物血脂沉积相关的病症,特别是涉及2型糖尿病和高脂血症的疾病特别有效。 本发明还涉及一种用于预防或治疗哺乳动物的2型糖尿病和高脂血症的方法,其包括施用治疗有效量的( - ) - 氟酸盐的结晶固体和无定形形式的步骤。

    Crystalline solid and amorphous forms of (-)- halofenate and methods related thereto
    4.
    发明申请
    Crystalline solid and amorphous forms of (-)- halofenate and methods related thereto 有权
    ( - ) - 卤化物的结晶固体和无定形形式及其相关方法

    公开(公告)号:US20080221018A1

    公开(公告)日:2008-09-11

    申请号:US11408609

    申请日:2006-04-20

    摘要: The present invention provides crystalline solid and amorphous forms of (−)-halofenate. The crystalline solid forms may be used in various pharmaceutical compositions, and are particularly effective for the prevention and/or treatment of conditions associated with blood lipid deposition in a mammal, particularly those diseases related to Type 2 diabetes and hyperlipidemia. The invention also relates to a method for preventing or treating Type 2 diabetes and hyperlipidemia in a mammal comprising the step of administering a therapeutically effective amount of crystalline solid and amorphous forms of (−)-halofenate.

    摘要翻译: 本发明提供( - ) - 卤代苯甲酸酯的结晶固体和无定形形式。 结晶固体形式可以用于各种药物组合物中,并且对于预防和/或治疗与哺乳动物血脂沉积相关的病症,特别是涉及2型糖尿病和高脂血症的疾病特别有效。 本发明还涉及一种用于预防或治疗哺乳动物的2型糖尿病和高脂血症的方法,其包括施用治疗有效量的( - ) - 氟酸盐的结晶固体和无定形形式的步骤。

    Preparation of a trans-calanolide ketone intermediate and chiral separation of calanolide alcohols to give racemic calanolide A
    5.
    发明授权
    Preparation of a trans-calanolide ketone intermediate and chiral separation of calanolide alcohols to give racemic calanolide A 失效
    制备反式丙烯醇酮中间体和手性分离甘油醇醇,得到外消旋的丙内酰胺A

    公开(公告)号:US06777562B1

    公开(公告)日:2004-08-17

    申请号:US10369984

    申请日:2003-02-19

    申请人: Edward D. Daugs

    发明人: Edward D. Daugs

    IPC分类号: C07D49314

    CPC分类号: C07D493/14

    摘要: The method of the invention comprises a process for synthesizing a trans-calanolide A ketone intermediate used in the synthesis of racemic trans-calanolide A. The invention further comprises a method for removing a racemic calanolide B diastereomer from a mixture of calanolide A and calanolide B diastereomers formed in the last step of the synthesis of calanolide A by crystallization.

    摘要翻译: 本发明的方法包括合成用于合成外消旋反式 - 正切内酯A的反式正己内酯A酮中间体的方法。本发明还包括一种从胼cal醇A和卡立拉宁B的混合物中除去外消旋的丙烯内酯B非对映异构体的方法 在通过结晶合成甘露糖苷A的最后步骤中形成的非对映异构体。

    Process for reducing inorganics from and concentrating anionic surfactant solutions
    6.
    发明授权
    Process for reducing inorganics from and concentrating anionic surfactant solutions 有权
    从阴离子表面活性剂溶液中减少无机物并浓缩的方法

    公开(公告)号:US08987506B2

    公开(公告)日:2015-03-24

    申请号:US13242963

    申请日:2011-09-23

    申请人: Edward D. Daugs

    发明人: Edward D. Daugs

    IPC分类号: C07C309/00 C07C303/44

    CPC分类号: C07C303/44 C07C309/10

    摘要: A process including contacting one or more Strecker sulfonation reaction products of one or more halogenated alkyl ethers in the presence of sulfite with one or more polar water soluble organic solvents selected from acetone, methyl ethyl ketone, the C2-C5 alkyl alcohols, and the like, to form an extraction mixture; allowing the extraction mixture to separate into an aqueous phase and an organic phase; and separating the aqueous phase from the organic phase; wherein the one or more Strecker sulfonation reaction products each comprise at least 30 percent by weight of one or more inorganic salts and the organic phase following separation comprises less than 20 percent by weight of one or more inorganic salts, is provided.

    摘要翻译: 一种方法,包括在亚硫酸盐存在下使一种或多种卤代烷基醚的一种或多种磺化反应产物与一种或多种选自丙酮,甲基乙基酮,C 2 -C 5烷基醇等的极性水溶性有机溶剂接触 ,形成提取混合物; 使萃取混合物分离成水相和有机相; 并将水相与有机相分离; 其中一个或多个Strecker磺化反应产物各自包含至少30重量%的一种或多种无机盐,分离后的有机相包含小于20重量%的一种或多种无机盐。

    Crystalline Solid and Amorphous Forms of (-)-Halofenate and Methods Related Thereto
    9.
    发明申请
    Crystalline Solid and Amorphous Forms of (-)-Halofenate and Methods Related Thereto 有权
    ( - ) - 卤化物的结晶固体和无定形形式及其相关方法

    公开(公告)号:US20120232303A1

    公开(公告)日:2012-09-13

    申请号:US13470142

    申请日:2012-05-11

    IPC分类号: C07C233/18

    摘要: The present invention provides crystalline solid and amorphous forms of (−)-halofenate. The crystalline solid forms may be used in various pharmaceutical compositions, and are particularly effective for the prevention and/or treatment of conditions associated with blood lipid deposition in a mammal, particularly those diseases related to Type 2 diabetes and hyperlipidemia. The invention also relates to a method for preventing or treating Type 2 diabetes and hyperlipidemia in a mammal comprising the step of administering a therapeutically effective amount of crystalline solid and amorphous forms of (−)-halofenate.

    摘要翻译: 本发明提供( - ) - 卤代苯甲酸酯的结晶固体和无定形形式。 结晶固体形式可以用于各种药物组合物中,并且对于预防和/或治疗与哺乳动物血脂沉积相关的病症,特别是涉及2型糖尿病和高脂血症的疾病特别有效。 本发明还涉及一种用于预防或治疗哺乳动物的2型糖尿病和高脂血症的方法,其包括施用治疗有效量的( - ) - 氟酸盐的结晶固体和无定形形式的步骤。